Oral Session 2-14A CAR T Therapy

[OS2-14A-4] Reduction of myeloid derived cytokines during CAR-T cell therapy prevents CRS and neurotoxicity

Reona Sakemura^1,2, Michelle J. Cox^1,2, Rosalie_M Sterner¹, Roman_H Khadka³, Nan Yang^1,5, Michael J. Hansen³, Fang Jin³, Kendall_J Schick^1,2, Mehrdad Hefazi^1,2, Michael_W Ruff^1,4, Neil_E Kay², Aaron_J Johnson³, Saad_S Kenderian^1,2,3 (1.T cell engineering laboratory, Mayo Clinic, Rochester, MN, United States of America, 2.Division of Hematology, Mayo Clinic, Rochester, MN, United States of America, 3.Department of Immunology, Mayo Clinic, Rochester, MN, United States of America, 4.Department of Neurology, Mayo Clinic, Rochester, MN, United States of America, 5.Department of Hematology, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi, People's Republic of China)